Clinical

Dataset Information

0

A Study of HY-0102 in Patients With Advanced Solid Tumors

ABSTRACT: This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of HY-0102 administered intravenously (IV) once every two weeks in patients with advanced solid tumors, so as to confirm the recommended phase 2 dose of HY-0102 and obtain the preliminary efficacy information of patients with advanced solid tumors.

DISEASE(S): Colorectal Cancer,Advanced Solid Tumor,Pancreatic Cancer,Neoplasms

PROVIDER: 114258 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical A Study of YL-17231 in Patients With Advanced Solid Tumors
| 108891 | ecrin-mdr-crc
Clinical A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
| 2752377 | ecrin-mdr-crc
Clinical A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
| 2343954 | ecrin-mdr-crc
Genomics CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
| PRJNA1205748 | ENA
Clinical A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors
| 2374163 | ecrin-mdr-crc
Clinical A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
| 2297511 | ecrin-mdr-crc
Genomics Advanced Genetic and Molecular Analysis of Solid Tumors
| PRJNA615693 | ENA
Genomics Clinical Implication of RAF1 aberrations in advanced solid tumors using next generation sequencing: a pan-tumor analysis
| PRJEB70258 | ENA
Genomics Advanced Genetic and Molecular Analysis of Solid Tumors
| PRJNA615692 | ENA
Proteomics Global proteome profiling of Ulixertinib treated neuroblastoma cell
2021-05-25 | MSV000087511 | MassIVE